- Home
- BPT vs NRXS Comparison
BPT vs NRXS Comparison
Compare BPT & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BPT
- NRXS
- Stock Information
- Founded
- BPT 1989
- NRXS 2011
- Country
- BPT United States
- NRXS United States
- Employees
- BPT N/A
- NRXS N/A
- Industry
- BPT Integrated oil Companies
- NRXS
- Sector
- BPT Energy
- NRXS
- Exchange
- BPT Nasdaq
- NRXS Nasdaq
- Market Cap
- BPT 11.7M
- NRXS 13.0M
- IPO Year
- BPT N/A
- NRXS 2023
- Fundamental
- Price
- BPT $0.63
- NRXS $2.61
- Analyst Decision
- BPT
- NRXS
- Analyst Count
- BPT 0
- NRXS 0
- Target Price
- BPT N/A
- NRXS N/A
- AVG Volume (30 Days)
- BPT 76.0K
- NRXS 4.9M
- Earning Date
- BPT 06-17-2025
- NRXS 05-12-2025
- Dividend Yield
- BPT N/A
- NRXS N/A
- EPS Growth
- BPT N/A
- NRXS N/A
- EPS
- BPT N/A
- NRXS N/A
- Revenue
- BPT $211,000.00
- NRXS $2,934,945.00
- Revenue This Year
- BPT N/A
- NRXS $138,883.78
- Revenue Next Year
- BPT N/A
- NRXS $118.59
- P/E Ratio
- BPT N/A
- NRXS N/A
- Revenue Growth
- BPT N/A
- NRXS 27.52
- 52 Week Low
- BPT $0.40
- NRXS $1.33
- 52 Week High
- BPT $2.61
- NRXS $6.20
- Technical
- Relative Strength Index (RSI)
- BPT 52.72
- NRXS 50.48
- Support Level
- BPT $0.61
- NRXS $2.57
- Resistance Level
- BPT $0.67
- NRXS $2.82
- Average True Range (ATR)
- BPT 0.03
- NRXS 0.44
- MACD
- BPT -0.00
- NRXS -0.05
- Stochastic Oscillator
- BPT 28.57
- NRXS 10.25
About BPT BP Prudhoe Bay Royalty Trust
BP Prudhoe Bay Royalty Trust is a grantor trust operating in the US. The property of the Trust consists of an overriding royalty interest. The Royalty Interest entitles the Trust to receive the royalty from the production of crude oil and condensate from the working interest of BP Exploration (Alaska) Inc. in the Prudhoe Bay oil field located on the North Slope of Alaska.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).